Tekla Life Valuation
| XHQLX Fund | USD 15.21 0.11 0.72% |
Based on Macroaxis valuation methodology, the fund is overvalued. Tekla Life Sciences has a current Real Value of $13.86 per share. The regular price of the fund is $15.21. Our model measures the value of Tekla Life Sciences from inspecting the fund technical indicators and probability of bankruptcy. In general, investors recommend acquiring undervalued mutual funds and dropping overvalued mutual funds since, at some point, mutual fund prices and their ongoing real values will draw towards each other.
Tekla Life Total Value Analysis
Tekla Life Sciences is at this time expected to have takeover price of 0 with market capitalization of 0, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Tekla Life fundamentals before making investing decisions based on enterprise value of the companyTekla Life Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Tekla suggests not a very effective usage of assets in January.About Tekla Life Valuation
Our relative valuation model uses a comparative analysis of Tekla Life. We calculate exposure to Tekla Life's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tekla Life's related companies.Other Information on Investing in Tekla Mutual Fund
Tekla Life financial ratios help investors to determine whether Tekla Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tekla with respect to the benefits of owning Tekla Life security.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |